Dobesilic Acid

Dobesilic Acid

SCHEMBL78222

O=S(=O)(O)c1cc(O)ccc1O.[KH]

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.70
HSD17B10 Q99714 3/20 0.70
HPGD P15428 1/20 0.70
HIF1A Q16665 1/20 0.70
PTGS1 P23219 1/20 0.61
EGFR P00533 1/20 0.56
GAA P10253 3/20 0.55
POLB P06746 2/20 0.55
GFER P55789 1/20 0.55
ALPL P05186 1/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
DNMT1 P26358 1/20 0.53
MCL1 Q07820 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
ALDH1A1 P00352 3/20 0.49
PKM P14618 1/20 0.49
MPL P40238 2/20 0.43
NSD2 O96028 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dobesilic Acid SCHEMBL370202 1.00 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL232087 0.98 LMNA (0.72) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL29389625 0.98 LMNA (0.72) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL9790423 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL10589964 0.95 HSD17B10 (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL344443 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL214799 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL78224 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL15364076 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1
Dobesilic Acid SCHEMBL866670 0.95 LMNA (0.70) LMNAHSD17B10HPGDHIF1APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436045-B2 Use of 2,5-dihydroxybenzene derivatives for treating actinic keratosis AmDerma Pharmaceuticals, LLC (US) 2013-05-07 US claimed
US-20120149938-A1 Processes For The Preparation Of 2,5-Dihydroxybenzenesulfonic Acid Salts AmDerma Pharmaceuticals, LLC (US) 2012-06-14 US claimed
US-20110144337-A1 PROCESSES FOR THE PREPARATION OF 2,5-DIHYDROXYBENZENESULFONIC ACID SALTS ACTION MEDICINES S.L. (ES) 2011-06-16 US claimed
EP-2313366-A2 PROCESSES FOR THE PREPARATION OF 2,5-DIHYDROXYBENZENESULFONIC ACID SALTS Action Medicines, S.L. (ES) 2011-04-27 EP claimed
WO-2009083940-A2 PROCESSES FOR THE PREPARATION OF 2,5-DIHYDROXYBENZENESULFONIC ACID SALTS ACTION MEDICINES S.L. (ES) 2009-07-09 WO claimed
US-6913694-B2 Selective membrane having a high fouling resistance SAEHAN INDUSTRIES INCORPORATION (KR) 2005-07-05 US claimed
US-20030121844-A1 Selective membrane having a high fouling resistance SAEHAN INDUSTRIES INCORPORATION (KR) 2003-07-03 US claimed
CN-117233312-A Detection method of related substances in hydroquinone cream and application thereof 广东人人康药业有限公司 2023-12-15 CN disclosed
CN-112023726-B Low-energy-consumption high-flux reverse osmosis membrane and preparation method and application thereof 万华化学集团股份有限公司 2022-07-12 CN disclosed
CN-112023726-A Low-energy-consumption high-flux reverse osmosis membrane and preparation method and application thereof 万华化学集团股份有限公司 2020-12-04 CN disclosed
US-10632085-B2 Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts AmDerma Pharmaceuticals, LLC (US) 2020-04-28 US disclosed
US-10632085-B2 Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts AmDerma Pharmaceuticals, LLC (US) 2020-04-28 US disclosed
US-20180289645-A1 Processes For The Preparation Of 2,5-Dihydroxybenzenesulfonic Acid Salts ACTION MEDICINES, S.L. (ES) 2018-10-11 US disclosed
US-20030121844-A1 Selective membrane having a high fouling resistance SAEHAN INDUSTRIES INCORPORATION (KR) 2003-07-03 US disclosed
US-6100020-A FORMING A SILVER HALIDE EMULSION, CHEMICAL OR OPTICAL SENSITIZATION, ADDING AN ARYL COMPOUND CONTAINING HYDROXY AND SULFONATE GROUPS, FINALLY COATING THE EMULSION EASTMAN KODAK COMPANY (US) 2000-08-08 US disclosed
EP-0903620-A1 Process for the preparation of silver halide photographic element Imation Corp. (US) 1999-03-24 EP disclosed
EP-0903621-A1 Process for the preparation of silver halide photographic element Imation Corp. (US) 1999-03-24 EP disclosed
EP-0524019-A1 Hydraulic cement mixtures containing (dialkanol)aminoalkylphenols W.R. Grace & Co.-Conn. (US) 1993-01-20 EP disclosed
US-5102467-A Adding a (dialkanol)aminomethyl phenol to enhance setting strength W.R. GRACE & CO.-CONN. (US) 1992-04-07 US disclosed
EP-0009837-B1 PHOTOGRAPHIC ELEMENT CONTAINING SUBSTITUTED 1-PHENYL-3-PYRAZOLIDINONE ELECTRON TRANSFER AGENT EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1984-02-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180289645-A1 Processes For The Preparation Of 2,5-Dihydroxybenzenesulfonic Acid Salts CYP24A1, CYP2S1, CYP21A2 LMNA 2713/4885HSD17B10 440/4885HPGD 854/4885
US-20110144337-A1 PROCESSES FOR THE PREPARATION OF 2,5-DIHYDROXYBENZENESULFONIC ACID SALTS KCNK5, CYP2S1, CYP26B1 LMNA 2394/4885HSD17B10 279/4885HPGD 930/4885
US-20120149938-A1 Processes For The Preparation Of 2,5-Dihydroxybenzenesulfonic Acid Salts KCNK5, CYP2S1, CYP26B1 LMNA 2394/4885HSD17B10 279/4885HPGD 930/4885
US-10632085-B2 Processes for the preparation of 2,5-dihydroxybenzenesulfonic acid salts CYP24A1, CYP2S1, CYP21A2 LMNA 2713/4885HSD17B10 440/4885HPGD 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.